BR112014002817A2 - Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62 - Google Patents

Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62 Download PDF

Info

Publication number
BR112014002817A2
BR112014002817A2 BR112014002817A BR112014002817A BR112014002817A2 BR 112014002817 A2 BR112014002817 A2 BR 112014002817A2 BR 112014002817 A BR112014002817 A BR 112014002817A BR 112014002817 A BR112014002817 A BR 112014002817A BR 112014002817 A2 BR112014002817 A2 BR 112014002817A2
Authority
BR
Brazil
Prior art keywords
polypeptide
nucleic acid
acid encoding
compositions
cancer
Prior art date
Application number
BR112014002817A
Other languages
English (en)
Inventor
Alexander Shneider
Franco Venanzi
Michael Sherman
Victor Shifrin
Original Assignee
Curelab Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curelab Oncology Inc filed Critical Curelab Oncology Inc
Publication of BR112014002817A2 publication Critical patent/BR112014002817A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62. são fornecidas aqui novas composições de p62 para a profilaxia e tratamento de câncer e usos relacionados. a invenção também fornece composições de p62 modificadas que aumentam a atividade anticâncer de p62.
BR112014002817A 2011-08-08 2012-08-08 Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62 BR112014002817A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161521280P 2011-08-08 2011-08-08
RU2012108927 2012-03-11
PCT/US2012/050024 WO2013022991A2 (en) 2011-08-08 2012-08-08 Methods and compositions relating to p62 for the treatment and prophylaxis of cancer

Publications (1)

Publication Number Publication Date
BR112014002817A2 true BR112014002817A2 (pt) 2021-09-08

Family

ID=47669212

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014002817A BR112014002817A2 (pt) 2011-08-08 2012-08-08 Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62

Country Status (15)

Country Link
US (3) US9717781B2 (pt)
EP (1) EP2750694B8 (pt)
JP (1) JP6193231B2 (pt)
KR (1) KR102001582B1 (pt)
CN (1) CN103889440A (pt)
AU (1) AU2012294454B2 (pt)
BR (1) BR112014002817A2 (pt)
CA (1) CA2844283C (pt)
CL (1) CL2014000291A1 (pt)
EA (1) EA026228B1 (pt)
HK (1) HK1200086A1 (pt)
IL (1) IL230770A0 (pt)
MX (1) MX353299B (pt)
SG (1) SG2014008411A (pt)
WO (1) WO2013022991A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441810B2 (en) * 2007-04-08 2019-10-15 Immunolight, Llc X-ray psoralen activated cancer therapy (X-PACT)
SG2014008411A (en) * 2011-08-08 2014-03-28 Curelab Oncology Inc Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
US20130345143A1 (en) * 2012-01-31 2013-12-26 Rutgers, The State University Of New Jersey MODULATION OF p62 FUNCTION THROUGH THE PB1 DOMAIN
WO2014154866A1 (en) * 2013-03-29 2014-10-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceuticals compositions for treating breast cancers
WO2015100446A1 (en) 2013-12-29 2015-07-02 Curelab Oncology, Inc. Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases
CN105079780B (zh) * 2014-05-04 2020-07-14 中国医学科学院药物研究所 一种特异结合trb3的多肽在治疗腹主动脉瘤中的应用
WO2016082192A1 (zh) * 2014-11-28 2016-06-02 中国医学科学院药物研究所 与trb3蛋白特异性结合的多肽，其筛选方法、鉴定和用途
CN106063928B (zh) * 2015-04-23 2020-07-14 中国医学科学院药物研究所 一种多肽或其衍生物在治疗高血压性心肌肥厚中的应用
WO2016207730A1 (en) * 2015-06-22 2016-12-29 The University Of Oslo Targeting of vaccine antigen to an intracellular compartment
EP3365017A4 (en) 2015-10-19 2019-04-17 Immunolight, LLC X-PACT ACTIVATED ANTI-CANCER TREATMENT BASED ON X-RAY-ACTIVATED PSORALENE
WO2018029256A1 (en) 2016-08-09 2018-02-15 Aarhus Universitet Modulation of ifi16 and sting activity
CN106153922B (zh) * 2016-09-14 2018-03-06 深圳大学 一种结肠癌预后预测标志物及其检测方法
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
AU2019217577A1 (en) * 2018-02-06 2020-09-24 Stipe Therapeutics Aps Modulation of P62 and STING activity
US20210220437A1 (en) * 2018-08-02 2021-07-22 Curelab Oncology, Inc. Compositions and Methods Relating to p62 for the Treatment and Prophylaxis of Age-Related Macular Degeneration
KR20240008294A (ko) * 2020-12-15 2024-01-18 상뜨르 나쇼날 드 라 러쉐르쉬 샹띠피끄 Sqstm1 및 암 치료법에서의 이의 용도
CN114106207B (zh) * 2022-01-24 2022-04-26 诺未科技（北京）有限公司 Ccl5的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
ATE132195T1 (de) 1987-03-02 1996-01-15 Whitehead Biomedical Inst Rekombinant-mykobakterielle impfstoffe
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
WO1991013157A1 (en) 1990-02-26 1991-09-05 Commonwealth Scientific And Industrial Research Organisation Shuttle plasmid for escherichia coli and mycobacteria
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5610276A (en) 1991-05-17 1997-03-11 Chiron Corporation Polypeptides and antibodies derived from GAP associated protein, p62
WO1992021376A1 (en) 1991-06-06 1992-12-10 Med Immune, Inc. Induction of ctl responses to foreign antigens expressed in mycobacteria
FR2734826B1 (fr) * 1995-06-01 1997-07-04 Rhone Poulenc Rorer Sa Deltap62, ses variants, sequences nucleiques et leurs utilisations
US5962224A (en) * 1995-12-19 1999-10-05 Dana-Farber Cancer Institute Isolated DNA encoding p62 polypeptides and uses therefor
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
KR20020013463A (ko) 1998-08-18 2002-02-20 와일러 제임스 에프. 유전자의 발현을 증강시키고 제한하는 방법
WO2001093897A2 (en) 2000-06-02 2001-12-13 Entremed, Inc. Angiostatin and endostatin binding proteins and methods of use
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
US7435872B2 (en) * 2002-05-14 2008-10-14 Jaekyoon Shin Role of p62 in aging-related disease
WO2005056598A2 (en) 2003-12-12 2005-06-23 Novo Nordisk A/S Laminin-5 modulators and uses thereof
US8444973B2 (en) * 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
CN102822200A (zh) * 2009-07-20 2012-12-12 百时美施贵宝公司 对增殖性疾病进行协同性治疗的抗ctla-4抗体与各种治疗方案的组合
WO2011083637A1 (ja) * 2010-01-07 2011-07-14 財団法人東京都医学総合研究所 肝疾患治療薬
SG2014008411A (en) * 2011-08-08 2014-03-28 Curelab Oncology Inc Methods and compositions relating to p62 for the treatment and prophylaxis of cancer

Also Published As

Publication number Publication date
MX2014001418A (es) 2014-09-15
EA201490423A1 (ru) 2014-07-30
HK1200086A1 (en) 2015-07-31
JP2014527053A (ja) 2014-10-09
JP6193231B2 (ja) 2017-09-06
US10716837B2 (en) 2020-07-21
AU2012294454B2 (en) 2017-02-02
EP2750694A2 (en) 2014-07-09
US20200338176A1 (en) 2020-10-29
US20140161824A1 (en) 2014-06-12
WO2013022991A2 (en) 2013-02-14
SG2014008411A (en) 2014-03-28
KR102001582B1 (ko) 2019-07-18
EP2750694B1 (en) 2018-09-19
CL2014000291A1 (es) 2014-08-08
AU2012294454A1 (en) 2014-02-13
US20170043002A1 (en) 2017-02-16
CA2844283C (en) 2024-06-04
CN103889440A (zh) 2014-06-25
KR20140083976A (ko) 2014-07-04
EA026228B1 (ru) 2017-03-31
MX353299B (es) 2018-01-08
WO2013022991A3 (en) 2013-04-18
IL230770A0 (en) 2014-03-31
CA2844283A1 (en) 2013-02-14
EP2750694B8 (en) 2018-11-14
US9717781B2 (en) 2017-08-01
EP2750694A4 (en) 2015-04-15

Similar Documents

Publication Publication Date Title
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
CO2017011851A2 (es) Compuestos novedosos
PH12015502553A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
BR112016012860A2 (pt) Compostos de biarila úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia
BR112016024644A2 (pt) vacinas de ácido nucleico
BR112017008976A2 (pt) ?composição, métodos de aumento da viscosidade de composições aquosas, de tratamento de material, de produção de dextrano e reação enzimática?
CL2014003465A1 (es) Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer.
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
EA201492221A1 (ru) Полипептиды, имеющие активность трансгалактозилирования
CL2015002501A1 (es) Compuestos y usos de estos para la modulación de la hemoglobina
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
MX2016008448A (es) Conjugados de var2csa-farmaco.
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
CO7020867A2 (es) Formulaciones de anticuerpo y metodos
MX2017003211A (es) Anticuerpos anti-met y composiciones.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
GT201800102A (es) Polipéptidos que inhiben cd4ol

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.11 NA RPI NO 2450 DE 19/12/2017.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.